DAWNGBX

Day One Biopharmaceuticals I

+$1.1B

Net Activity

Institutions Holding

209

Popularity Rank

#2779

Avg Weight

0.25%

Total Value

$1.9B

Ownership Trend

209 institutions currently hold DAWNGBX, with 138 net buyers and 106 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

106

Net Buying Institutions

138

Key Holders

View all 209 holding institutions

Quarterly Activity

Recent Activity

+$1.3B

Total Buy Value

$558.4M

Total Sell Value

New buy74
Trim48
Add64
Sold out58

138

Net Buyers

106

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding DAY ONE BIOPHARMACEUTICALS I (DAWNGBX)?
Major stakeholders currently include BlackRock, Inc. ($151.0M), Glazer Capital, LLC ($100.4M), FIL Ltd ($88.6M). Based on the latest 13F filings, there are a total of 209 tracked investment funds and institutions maintaining positions in DAWNGBX.
What is the overall institutional sentiment toward DAWNGBX recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $1.1B, driven by 138 managers accumulating shares while 106 reduced their exposure.
Which institutions have been selling or reducing their DAWNGBX positions?
In the latest period, 48 funds trimmed their holdings, and 58 managers completely exited their positions. The aggregate reported sell value was $558.4M.
Are there any notable investors adding DAWNGBX to their portfolios?
Yes, buying activity remains notable. 74 institutions opened new positions in {ticker}, and 64 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.3B.

Related Stocks